4D Molecular Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
4D Molecular Therapeutics, Inc. (FDMT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 293.10 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-13
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 276.97K shares, a 22.98% decline year-over-year.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 16.13K shares, a 78.35% decline year-over-year.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 89.92K shares, a 8.74% decline year-over-year.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 979.99K shares, a 2495.09% increase year-over-year.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 1.50M shares, a 379.36% increase from fiscal 2024.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 313.76K shares, a 52.45% decline from fiscal 2023.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 659.82K shares, a 60.06% increase from fiscal 2022.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 412.24K shares, a 32.43% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 276.97K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 293.10K shares 10-Q · filed 2026-08-13 | 383.02K shares derived: sum of 3 quarters · filed 2026-08-13 | 1.36M shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 16.13K shares 10-Q · filed 2026-05-07 | 106.05K shares derived: sum of 2 quarters · filed 2026-05-07 | 1.09M shares derived: sum of 3 quarters · filed 2026-05-07 | 1.45M shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 89.92K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | 1.07M shares derived: sum of 2 quarters · filed 2026-03-18 | 1.43M shares derived: sum of 3 quarters · filed 2026-03-18 | 1.50M shares 10-K · filed 2026-03-18 |
| 2025-09-30 | 979.99K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | 1.34M shares derived: sum of 2 quarters · filed 2025-11-10 | 1.41M shares 10-Q · filed 2025-11-10 | 1.51M shares derived: sum of 4 quarters · filed 2025-11-10 |
| 2025-06-30 | 359.61K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | 434.13K shares 10-Q · filed 2025-08-11 | 532.66K shares derived: sum of 3 quarters · filed 2025-08-11 | 570.42K shares derived: sum of 4 quarters · filed 2025-08-11 |
| 2025-03-31 | 74.51K shares 10-Q · filed 2025-05-08 | 173.05K shares derived: sum of 2 quarters · filed 2025-05-08 | 210.81K shares derived: sum of 3 quarters · filed 2025-05-08 | 323.19K shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 98.53K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | 136.30K shares derived: sum of 2 quarters · filed 2025-02-28 | 248.67K shares derived: sum of 3 quarters · filed 2025-02-28 | 313.76K shares 10-K · filed 2025-02-28 |
| 2024-09-30 | 37.76K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 150.14K shares derived: sum of 2 quarters · filed 2024-11-13 | 215.22K shares 10-Q · filed 2024-11-13 | 271.24K shares derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | 112.38K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 177.46K shares 10-Q · filed 2024-08-08 | 233.48K shares derived: sum of 3 quarters · filed 2024-08-08 | 565.23K shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 65.08K shares 10-Q · filed 2024-05-09 | 121.10K shares derived: sum of 2 quarters · filed 2024-05-09 | 452.86K shares derived: sum of 3 quarters · filed 2024-05-09 | 606.95K shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 56.02K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 387.77K shares derived: sum of 2 quarters · filed 2024-02-29 | 541.86K shares derived: sum of 3 quarters · filed 2024-02-29 | 659.82K shares 10-K · filed 2024-02-29 |
| 2023-09-30 | 331.75K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 485.84K shares derived: sum of 2 quarters · filed 2023-11-09 | 603.80K shares 10-Q · filed 2023-11-09 | 717.52K shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 154.09K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | 272.05K shares 10-Q · filed 2023-08-09 | 385.76K shares derived: sum of 3 quarters · filed 2023-08-09 | 472.99K shares derived: sum of 4 quarters · filed 2023-08-09 |
| 2023-03-31 | 117.96K shares 10-Q · filed 2023-05-11 | 231.67K shares derived: sum of 2 quarters · filed 2023-05-11 | 318.90K shares derived: sum of 3 quarters · filed 2023-05-11 | 423.52K shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 113.71K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | 200.94K shares derived: sum of 2 quarters · filed 2023-03-15 | 305.57K shares derived: sum of 3 quarters · filed 2023-03-15 | 412.24K shares 10-K · filed 2023-03-15 |
| 2022-09-30 | 87.22K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 191.85K shares derived: sum of 2 quarters · filed 2022-11-08 | 298.53K shares 10-Q · filed 2022-11-08 | 517.83K shares derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-06-30 | 104.63K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 211.30K shares 10-Q · filed 2022-08-11 | 430.60K shares derived: sum of 3 quarters · filed 2022-08-11 | 496.11K shares derived: sum of 4 quarters · filed 2022-08-11 |
| 2022-03-31 | 106.67K shares 10-Q · filed 2022-05-12 | 325.98K shares derived: sum of 2 quarters · filed 2022-05-12 | 391.48K shares derived: sum of 3 quarters · filed 2022-05-12 | 412.74K shares derived: sum of 4 quarters · filed 2022-05-12 |
| 2021-12-31 | 219.30K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | 284.81K shares derived: sum of 2 quarters · filed 2022-03-28 | 306.07K shares derived: sum of 3 quarters · filed 2022-03-28 | 311.28K shares 10-K · filed 2022-03-28 |
| 2021-09-30 | 65.51K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 86.77K shares derived: sum of 2 quarters · filed 2021-11-10 | 91.98K shares 10-Q · filed 2021-11-10 | |
| 2021-06-30 | 21.26K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | 26.47K shares 10-Q · filed 2021-08-12 | ||
| 2021-03-31 | 5.21K shares 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | 231.10K shares 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |